Pharmaceutical powerhouse Merck & Co. recently paid the Australian branch of Elsevier, a company that publishes a wide range of scholarly journals, to put together a bogus journal for them. This is bad behaviour on the part of both companies. No one is really all that surprised about Merck, I take it. But Elsevier should know better.
Physician & columnist, Ben Goldacre, has this nice summary of the situation: Elsevier get into fanzines.
Hat tip to Chris MacDonald.